Regulatory Watch
June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Glossary

Key terms and definitions used throughout PeptideExaminer.

503A Pharmacy
A traditional compounding pharmacy that prepares medications based on individual patient prescriptions. Subject to state pharmacy board oversight.
503B Outsourcing Facility
An FDA-registered compounding facility that can produce larger batches without individual prescriptions. Subject to FDA CGMP requirements.
Bioavailability
The percentage of an administered substance that reaches systemic circulation. Oral peptides typically have very low bioavailability due to degradation in the GI tract.
BPC-157
Body Protection Compound-157, a synthetic 15-amino-acid peptide derived from human gastric juice. FDA Category 2 (prohibited for compounding).
Category 1
FDA classification for bulk drug substances that may be used in compounding. Includes sermorelin, GHK-Cu (topical), VIP, and NAD+.
Category 2
Former FDA classification for substances prohibited from compounding due to safety concerns. Includes BPC-157, TB-500, and most popular peptides.
CGMP
Current Good Manufacturing Practice. FDA regulations ensuring pharmaceutical quality, including facility standards, testing, and documentation.
COA (Certificate of Analysis)
Laboratory documentation verifying a product's identity, purity, and quality. Should include HPLC, mass spectrometry, and for injectables, endotoxin testing.
DSHEA
Dietary Supplement Health and Education Act of 1994. Defines dietary supplements and their regulatory framework. Most peptides do not qualify as dietary supplements under DSHEA.
Endotoxin
Bacterial cell wall components (lipopolysaccharides) that can cause severe immune reactions. Critical safety concern for injectable products.
GLP-1
Glucagon-like peptide-1. A hormone that regulates blood sugar and appetite. Semaglutide and tirzepatide are GLP-1 receptor agonists.
Grey Market
Products sold outside official distribution channels, often labeled 'for research use only.' Not illegal to sell in some contexts, but not approved for human use.
HPLC
High-Performance Liquid Chromatography. Analytical technique used to measure peptide purity by separating compounds based on their chemical properties.
LAL Test
Limulus Amebocyte Lysate test. The standard method for detecting bacterial endotoxins in injectable products.
Lyophilized
Freeze-dried. Peptides are often sold as lyophilized powder for stability, requiring reconstitution with bacteriostatic water before use.
Mass Spectrometry
Analytical technique that measures molecular weight to confirm peptide identity. Essential for verifying you have the correct compound.
NDIN
New Dietary Ingredient Notification. Required submission to FDA before marketing a new dietary ingredient. No BPC-157 or similar peptide vendors have filed accepted NDINs.
PDA (Pentadeca Arginate)
BPC-157 with arginine as the counter-ion instead of acetate. Marketed as a distinct compound but contains the identical peptide sequence.
Peptide
A chain of amino acids linked by peptide bonds. Generally 2-50 amino acids; larger chains are typically called proteins.
Pharmacokinetics (PK)
How the body absorbs, distributes, metabolizes, and eliminates a drug. Includes measurements like half-life and bioavailability.
RCT
Randomized Controlled Trial. The gold standard for clinical evidence, where participants are randomly assigned to treatment or placebo groups.
SNAC
Salcaprozate sodium. Absorption enhancer used in Rybelsus (oral semaglutide) to enable oral peptide bioavailability.
TB-500
A 7-amino-acid fragment of Thymosin Beta-4 commonly sold on the grey market. Not the same as full-length Thymosin Beta-4 used in research.
WADA
World Anti-Doping Agency. Maintains the list of prohibited substances in sports. Most peptides including BPC-157 and TB-500 are prohibited.